Novel thiazole derivatives: a patent review (2008 – 2012; Part 1)

Bibliography

• Snyder NL, Boisvert CJ. Hantzsch synthesis. Name reactions in heterocyclic chemistry II. Jie-Jack Li editor, J. Wiley & Sons, Inc., Hoboken, New Jersey; 2011. p. 591-644
   Google Scholar
• Kemson J. Hantzsch thiazole synthesis. Name reactions in heterocyclic chemistry II. Jie-Jack Li editor, J. Wiley & Sons, Inc., Hoboken, New Jersey; 2011. p. 299-308
   Google Scholar
• Sundh UB, Binderup M-L, Brimer L, et al. Scientific opinion on flavouring group evaluation 21, Revision 3: thiazoles, thiophenes, thiazoline and thienyl derivatives from chemical groups 29 and 30. EFSA J 2012;10:2457-551
   Google Scholar
• Lin Y, Fan H, Li Y, et al. Thiazole-based organic semiconductors for organic electronics. Adv Mater 2012;24:3087-106
   PubMedGoogle Scholar
• Kathiravan MK, Salake AB, Chothe AS, et al. The biology and chemistry of antifungal agents: a review. Bioorg Med Chem 2012;20:5678-98
   PubMed Web of Science ®Google Scholar
• Kelly WL. Biosynthesis: ringing in a new view. Nat Chem Biol 2012;8:505-7
   PubMedGoogle Scholar
• Siddiqui N, Arya SK, Ahsan W, et al. Diverse biological activities of thiazoles: a retrospect. Int J Drug Dev Res 2011;55-67
   Google Scholar
• Foster FM, Traer CJ, Abraham SM, et al. The phosphoinositide (PI) 3-kinase family. J Cell Sci 2003;116:3037-40
   PubMed Web of Science ®Google Scholar
• Martelli AM, Evangelisti C, Chiarini F, et al. The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogenesis. Biochim Biophys Acta 2010;1803:991-1002
   PubMed Web of Science ®Google Scholar
• Fruman DA. Regulatory subunits of class IA PI3K. Phosphoinositide 3-kinase in health and disease. Volume 1 2010;346:225-44
   Google Scholar
• Alexander RP, Aujla PS, Crepy KVL, et al. Fused thiazole derivatives as PI3 kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases. US0137302A12; 2010
   Google Scholar
• Hancox TC, Beswick MC, Blench TJ, et al. Thiazolopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase. US0098270A1; 2011
   Google Scholar
• Genetech, Inc. and F. Hoffmann-La Roche AG. Thiazolopyrimidine PI3K inhibitor compounds and methods of use. US0112085; 2011
   Google Scholar
• Novartis AG. Substituted 2-carboxamide cycloamino ureas. WO000905; 2011
   Google Scholar
• Novartis AG. Pyrrolidine-1,2-dicarboxamide derivatives. US0263712A1; 2012
   Google Scholar
• Glaxo Group Ltd. Indazole derivatives as pi 3-kinase. US0238571; 2012
   Google Scholar
• Millennium Pharmaceuticals, Inc. Heteroaryls and uses threfor. US0172345A1; 2012
   Google Scholar
• Sallee JL, Wittchen ES, Burridge K. Regulation of cell adhesion by protein-tyrosine phosphatases - II. Cell-cell adhesion. J Biol Chem 2006;281:16189-92
   PubMed Web of Science ®Google Scholar
• Rosenblum JS, Nomanbhoy TK, Kozarich JW. Functional interrogation of kinases and other nucleotide-binding proteins. FEBS Lett 2013;587:1870-7
   PubMedGoogle Scholar
• Goff D, Zhang J, Singh R, et al. Diaminothiazoles useful as AXl inhibitors. US0227789A1; 2008
   Google Scholar
• Roussel MF, Dull TJ, Rettenmier CW, et al. Transforming potential of the c-fms protooncogene (CSF-1 receptor). Nature 1987;325:549-52
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb Co. Thiazolyl compounds useful as kinase inhibitors. WO079873; 2008
   Google Scholar
• Mathis G. HTRF® technology. J Biomol Screen 1999;4:309-13
   PubMed Web of Science ®Google Scholar
• Abbott Laboratories. Protein kinase inhibitors. US0253723A1; 2009
   Google Scholar
• Bristol-Myers Squibb Co. Thiazolyl compounds usefull as kinase inhibitors. US0120770A1; 2010
   Google Scholar
• Mariner AQC, Dodier M, Dodier M, et al. Thiazolyl compounds useful as kinase inhibitors. US0048581A1; 2010
   Google Scholar
• Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005;5:341-54
   PubMed Web of Science ®Google Scholar
• Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999;82:241-50
   PubMed Web of Science ®Google Scholar
• Thomas MB, Chadha R, Glover K, et al. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 2007;110:1059-67
   PubMed Web of Science ®Google Scholar
• Huether A, Hopfner M, Sutter AP, et al. Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics. J Hepatol 2005;43:661-9
   PubMed Web of Science ®Google Scholar
• Adjabeng G, Bifulco N, Davis-ward RG, et al. Thiazole and oxazole kinase inhibitors. US0098296; 2011
   Google Scholar
• Adjabeng G, Bifulco N, Davis-ward RG, et al. Thiazole sulphonamide and oxazole sulfonamide kinase inhibitors. US0319392; 2011
   Google Scholar
• Adjabeng G, Bifulco N, Davis-ward RG, et al. Thiazole and oxazole kinase inhibitors. US10190280; 2011
   Google Scholar
• Boston Biomedicals, Inc. Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases. US0321622A1; 2012
   Google Scholar
• Yu V, Pistillo J, Archibeque I, et al. Differential selectivity of JAK2 inhibitors in enzymatic and cellular settings. Exp Hematol 2013;41:491-500
   PubMedGoogle Scholar
• Wilks AF. The JAK kinases: not just another kinase drug discovery target. Semin Cell Dev Biol 2008;19:319-28
   PubMed Web of Science ®Google Scholar
• Blench JT, Ellwood C, Goodacre CS, et al. Azabenzothiazole compounds, compositions and methods of use. US0202788A1; 2012
   Google Scholar
• Freeman SM, Whartenby KA. The role of the mitogen-activated protein kinase cellular signaling pathway in tumor cell survival and apoptosis. Drug News Perspect 2004;17:237-42
   PubMedGoogle Scholar
• Warner SL, Bearss DJ, Han H, et al. Targeting aurora-2 kinase in cancer. Mol Cancer Ther 2003;2:589-95
   PubMed Web of Science ®Google Scholar
• Capra M, Nuciforo PG, Confalonieri S, et al. Frequent alterations in the expression of serine/threonine kinases in human cancers. Cancer Res 2006;66:8147-54
   PubMed Web of Science ®Google Scholar
• Kauffmann-Zeh A, Rodriguez-Viciana P, Ulrich E, et al. Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature 1997;385:544-8
   PubMed Web of Science ®Google Scholar
• Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase-AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501
   PubMed Web of Science ®Google Scholar
• Graff JR. Emerging targets in the AKT pathway for treatment of androgen-independent prostatic adenocarcinoma. Expert Opin Ther Targets 2002;6:103-13
   PubMedGoogle Scholar
• Agarwal E, Brattain MG, Chowdhury S. Cell survival and metastasis regulation by Akt signaling in colorectal cancer. Cell Signal 2013;25:1711-19
   PubMed Web of Science ®Google Scholar
• Nakatani K, Thompson DA, Barthel A, et al. Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J Biol Chem 1999;274:21528-32
   PubMed Web of Science ®Google Scholar
• Bellacosa A, Defeo D, Godwin AK, et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer 1995;64:280-5
   PubMed Web of Science ®Google Scholar
• Chin YR, Toker A. AKT isoform-specific signaling in breast cancer: uncovering an anti-migratory role of palladin. Cell Adh Migr 2011;5:211-14
   PubMed Web of Science ®Google Scholar
• Chen SF, Chen JZ. Development for anticancer therapy: small-molecule inhibitors targeting protein kinase B. Mini Rev Med Chem 2013;13:1272-94
   PubMedGoogle Scholar
• Dickson KJ, Nicholas C, Chen K. 2-Amido-4-isoxazolyl thiazole compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof. US0242709; 2008
   Google Scholar
• Amgen, Inc. Fluoroisoquinoline substituted thiazole compounds and methods of use. US0263647; 2011
   Google Scholar
• Rouse MB, Seefeld MA. Preparation of thiazole and oxazole compounds as inhibitors of Akt activity useful in treatment of cancer and arthritis. US0160255A1; 2011
   Google Scholar
• Caffrey DR, Lunney EA, Moshinsky DJ. Prediction of specificity-determining residues for small-molecule kinase inhibitors. BMC Bioinformatics 2008;9:491
   PubMedGoogle Scholar
• Vertex Pharmaceuticals, Inc. Inhibitors of Aurora-2, glycogen synthase kinase-3 and Src kinase. Expert Opin Ther Patents 2004;14:439-43
   Google Scholar
• Vertex Pharmaceuticals, Inc. Thiazoles and pyrazoles useful as kinase inhibitors. US0317641; 2010
   Google Scholar
• Schering Corp. Thiazole derivatives as protein kinase inhibitors. US0331313; 2010
   Google Scholar
• Schering Corp. Diamido thiazole derivatives as protein kinase inhibitors. WO058730; 2009
   Google Scholar
• Sbi Biotech, Ltd and Crystalgenomics, Inc. Thizolidinone derivative. US019299; 2011
   Google Scholar
• Gregoretti IV, Lee YM, Goodson HV. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol 2004;338:17-31
   PubMed Web of Science ®Google Scholar
• Dasmahapatra G, Almenara JA, Grant S. Flavopiridol and histone deacetylase inhibitors promote mitochondrial injury and cell death in human leukemia cells that overexpress Bcl-2. Mol Pharmacol 2006;69:288-98
   PubMed Web of Science ®Google Scholar
• Grant S, Dent P. Simultaneous interruption of signal transduction and cell cycle regulatory pathways: implications for new approaches to the treatment of childhood leukemias. Curr Drug Targets 2007;8:751-9
   PubMed Web of Science ®Google Scholar
• Robak T, Szmigielska-Kaplon A, Pluta A, et al. Novel and emerging drugs for acute myeloid leukemia: pharmacology and therapeutic activity. Curr Med Chem 2011;18:638-66
   PubMed Web of Science ®Google Scholar
• Trisciuoglio D, Ragazzoni Y, Pelosi A, et al. CPTH6, a Thiazole derivative, induces histone hypoacetylation and apoptosis in human leukemia cells. Clin Cancer Res 2012;18:475-86
   PubMedGoogle Scholar
• Qian C, Cai X, Zhai H. Preparation of oxazolylmethylthiothiazoles as CDK inhibitors containing a zinc binding moiety. WO036016A1; 2009
   Google Scholar
• Scott RW, Olson MF. LIM kinases: function, regulation and association with human disease. J Mol Med 2007;85:555-68
   PubMed Web of Science ®Google Scholar
• Lexicon Pharmaceuticals, Inc. 5-(1H-Pyrazol-5-yl)thiazole-based compounds for the treatment of disease and disorders of the eye. WO091204; 2011
   Google Scholar
• Mattila E, Ivaska J. High-Throughput methods in identification of protein tyrosine phosphatase inhibitors and activators. Anticancer Agents Med Chem 2011;11:141-50
   PubMedGoogle Scholar
• Gray JL, Clark CM, Nichols RM, et al. Human protein tyrosine phosphatase inhibitors and method of use. US0077975; 2012
   Google Scholar
• Nguyen LL, D'Amore PA. Cellular interactions in vascular growth and differentiation. Int Rev Cytol 2001;204:1-48
   PubMed Web of Science ®Google Scholar
• Bussolino F, Mantovani A, Persico G. Molecular mechanisms of blood vessel formation. Trends Biochem Sci 1997;22:251-6
   PubMed Web of Science ®Google Scholar
• Auerbach R, Lewis R, Shinners B, et al. Angiogenesis assays: a critical overview. Clin Chem 2003;49:32-40
   PubMed Web of Science ®Google Scholar
• Vailhé B, Vittet D, Feige JJ. In vitro models of vasculogenesis and angiogenesis. Lab Invest 2001;81:439-52
   PubMed Web of Science ®Google Scholar
• Lewis GF, Carpentier A, Adeli K, et al. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 2002;23:201-29
   PubMed Web of Science ®Google Scholar
• Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA 2002;287:356-9
   PubMed Web of Science ®Google Scholar
• Cases S, Stone SJ, Zhou P, et al. Cloning of DGAT2, a second mammalian diacylglycerol acyltransferase, and related family members. J Biol Chem 2001;276:38870-6
   PubMed Web of Science ®Google Scholar
• Zammit VA. Hepatic triacylglycerol synthesis and secretion: DGAT2 as the link between glycaemia and triglyceridaemia. Biochem J 2013;451:1-12
   PubMed Web of Science ®Google Scholar
• Smith SJ, Cases S, Jensen DR, et al. Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking Dgat. Nat Genet 2000;25:87-90
   PubMed Web of Science ®Google Scholar
• Chen HC, Smith SJ, Ladha Z, et al. Increased insulin and leptin sensitivity in mice lacking acyl CoA:diacylglycerol acyltransferase 1. J Clin Invest 2002;109:1049-55
   PubMed Web of Science ®Google Scholar
• Gouni-Berthold I, Bruning JC, Berthold HK. Novel approaches to the pharmacotherapy of obesity. Curr Pharm Des 2013;19:4938-52
   PubMedGoogle Scholar
• Cheon HG. Latest research and development trends in non-insulin anti-diabetics. Arch Pharm Res 2013;36:145-53
   PubMedGoogle Scholar
• Kim MO, Lee SU, Lee HJ, et al. Identification and validation of a selective small molecule inhibitor targeting the diacylglycerol acyltransferase 2 activity. Biol Pharm Bull 2013;36:1167-73
   PubMed Web of Science ®Google Scholar
• Judd AS, Mulhern MM, Iyengar RR, et al. Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme. US0312282A1; 2008
   Google Scholar
• Piramal Life Sciences Ltd. Diacylglycerol Acyltransferase Inhibitors. US10196002A1; 2011
   Google Scholar
• Ravindra DJ, Rajiv S, Kishorkumar SK, et al. Carboxy oxazole or thiazole compounds as dgat-1 inhibitors useful for the treatment of obesity. US0214854A1; 2012
   Google Scholar
• Chen HQ, Gu ZN, Zhang H, et al. Expression and purification of integral membrane fatty acid desaturases. PLoS One 2013;8,3,e58139
   Google Scholar
• Jeffcoat R, Roberts PA, Ormesher J, et al. Stearolyl-CoA desaturase: a control enzyme in hepatic lipogenesis. Eur J Biochem 1979;101:439-45
   PubMedGoogle Scholar
• Hodson L, Fielding BA. Stearoyl-CoA desaturase: rogue or innocent bystander? Prog Lipid Res 2013;52:15-42
   PubMed Web of Science ®Google Scholar
• Jeffcoat R. Obesity - A perspective based on the biochemical interrelationship of lipids and carbohydrates. Med Hypotheses 2007;68:1159-71
   PubMed Web of Science ®Google Scholar
• Novartis Institutes for Biomedical Research, Inc. Organic compounds. US0029722A1; 2010
   Google Scholar
• Shanklin J, Somerville C. Stearoyl-acyl-carrier-protein desaturase from higher-plants is structurally unrelated to the animal and fungal homologs. Proc Natl Acad Sci USA 1991;88:2510-14
   PubMed Web of Science ®Google Scholar
• Xenon Pharmaceuticals, Inc. and Novartis Ag. Organic compounds. US0014906A1; 2012
   Google Scholar
• Printz RL, Magnuson MA, Granner DK. Mammalian glucokinase. Annu Rev Nutr 1993;13:463-96
   PubMed Web of Science ®Google Scholar
• Meglasson MD, Matschinsky FM. New perspectives on pancreatic islet glucokinase. Am J Physiol 1984;246(1 Pt 1):E1-13
   Google Scholar
• Grupe A, Hultgren B, Ryan A, et al. Transgenic knockouts reveal a critical requirement for pancreatic beta-cell glucokinase in maintaining glucose-homeostasis. Cell 1995;83:69-78
   PubMed Web of Science ®Google Scholar
• Ferre T, Riu E, Bosch F, et al. Evidence from transgenic mice that glucokinase is rate limiting for glucose utilization in the liver. FASEB J 1996;10:1213-18
   PubMed Web of Science ®Google Scholar
• Glaser B, Kesavan P, Heyman M, et al. Familial hyperinsulinism caused by an activating glucokinase mutation. N Engl J Med 1998;338:226-30
   PubMed Web of Science ®Google Scholar
• Pfefferkorn JA. Strategies for the design of hepatoselective glucokinase activators to treat type 2 diabetes. Expert Opin Drug Discov 2013;8:319-30
   PubMed Web of Science ®Google Scholar
• Hoffmann-La Roche, Inc. Heteroaromatic glucokinase activators. US0014968A1; 2004
   Google Scholar
• Novo Nordisk A/S. Amide derivatives as GK activators. WO055482; 2003
   Google Scholar
• Bowler JM, Hervert KL, Kearley ML, et al. Small-molecule allosteric activation of human glucokinase in the absence of glucose. ACS Med Chem Lett 2013;4:580-4
   Google Scholar
• Murray A, Lau J, Vedso P, et al. Dicycloalkyl urea glucokinase activators. US7582769B2; 2009
   Google Scholar
• Nobel S, Abrahmsen L, Oppermann U. Metabolic conversion as a pre-receptor control mechanism for lipophilic hormones. Eur J Biochem 2001;268:4113-25
   PubMedGoogle Scholar
• Seckl JR, Walker BR. Minireview: 11beta-hydroxysteroid dehydrogenase type 1 - A tissue-specific amplifier of glucocorticoid action. Endocrinology 2001;142:1371-6
   PubMed Web of Science ®Google Scholar
• Lipson VV, Shirobokova MG, Petrova ON. 11beta-Hydroxysteroid dehydrogenase type 1, a target for development of oral antidiabetic drugs (Review). Pharm Chem J 2013;47:80-6
   Google Scholar
• Stokes J, Noble J, Brett L, et al. Distribution of glucocorticoid and mineralocorticoid receptors and 11beta-hydroxysteroid dehydrogenases in human and rat ocular tissues. Pharm Chem J 2000;41:1629-38
   Google Scholar
• Leriche C, Carniato D, Roche D, et al. Nip thiazole derivatives as inhibitors of 11beta-hydroxysteroid dehydrogenase-1. WO13558; 2009
   Google Scholar